Gene Therapy Maker Sarepta Defies FDA, Refuses to Halt Shipments
Gene therapy maker Sarepta Therapeutics has told the FDA it won’t stop shipping its treatment for muscular dystrophy despite a third patient’s death linked to liver injury. The company, which recently laid off 500 employees and cut prices of one of its existing treatments, claims there are no new safety concerns with its leading therapy, … Read more